Additional file 2: of Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study

Si, Lu; Zhang, Xiaoshi; Xu, Zhen; Jiang, Qiudi; Bu, Lilian; Wang, Xuan; Mao, Lili; Zhang, Weijiang; Richie, Nicole; Guo, Jun

doi:10.6084/m9.figshare.6220994.v1

12885_2018_4336_MOESM2_ESM.pdf (71.95 kB)

Additional file 2: of Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study

journal contribution

posted on 2018-05-03, 05:00 authored by Lu Si, Xiaoshi Zhang, Zhen Xu, Qiudi Jiang, Lilian Bu, Xuan Wang, Lili Mao, Weijiang Zhang, Nicole Richie, Jun Guo

Figure S1. Vemurafenib Ctrough concentrations (mean ± SD) after day 28 in the pharmacokinetics and expansion cohorts. SD standard deviation, CV coefficient of variation. (PDF 71 kb)

Funding

F. Hoffmann-La Roche

History

Usage metrics

Keywords

BRAF V600-positive Advanced melanoma Vemurafenib China Asia

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 2: of Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study

Funding

F. Hoffmann-La Roche

History

Usage metrics

Categories

Keywords

Licence

Exports